J&J shares slip, Facebook gains after hours
LOS ANGELES (MarketWatch) -- Shares of
J&J (JNJ) stock pulled back 0.2% at $62.85 as the company said it expects a special second-quarter charge of $600 million to settle civil suits on how it marketed certain drugs.
The charge will cover a potential settlement for civil charges that it marketed the drugs Risperdal, Invega and Natrecor for uses not approved by the Food and Drug Administration, and that it provided kickbacks to pharmaceutical-benefits manager
Late-traded Facebook (FB) shares picked up 0.6% to $27.25. The stock finished the day session up 3%, finding strength after Internet-data tracker comScore Inc. indicated that figures to be release next week will show Facebook's ads are more effective than investors think.
"We are gaining critical new insights that show Facebook earned media is having a statistically significant positive lift on people's purchasing of a brand," wrote Andrew Lipsman, vice president of industry analysis at comScore in a blog preview of the report. Read more on comScore's upcoming Facebook report.
Facebook shares closed the week with a loss of 2.2%, their third straight weekly decline. More on Facebook's weekly loss.
During the day session, U.S. stocks rose, marking their best week this year, with increased anticipation that Europe will move to combat its economic crisis, including a possible recapitalization of Spanish banks. Read more in Market Snapshot.
For the week, the Nasdaq rose 4%. The Dow advanced 3.6% and the S&P 500 Index ended higher by 3.7%.